MALAT1 and hepatocellular carcinoma: In conclusion, as we depicted in our schematic abstract (Figure 7), the present study provides evidence that the the molecular targeting of the lncRNA MALAT1 effectively depletes the CD133highCD90high HCC pool, inhibits the constitutive stemness of selected CD133highCD90high HCC cells, impairs the nuclear translocation of β-catenin, quells the aberrant activation of the Wnt/β-catenin, represses cisplatin-induced HCC-SCs enrichment, abrogates cancerous liver cell metastasis and clonogenicity, as well as suppresses in vivo tumor initiation and growth.